Fecal Microbiota Transplantation for IBD Needs Revision for Clinical Impact

Fecal Microbiota Transplantation for IBD Needs Revision for Clinical Impact
Fecal microbiota transplantationFecal microbiota transplantation (FMT), the transfer of fecal bacteria from a healthy donor to a recipient, was the topic of several studies presented during Digestive Disease Week 2014 held in May. Tests on human patients discussed at the meeting cannot yet conclusively add FMT to clinicians' toolbox of treating inflammatory bowel disease, but results suggest promise for the treatment. "Although we did not find a statistically significant effect of FMT in active ulcerative colitis, there is the possibility that FMT may be effective when administered longer than six weeks," stated the presenter for the first randomized trial for FMT in inflammatory bowel disease patients. The trial was led by Paul Moayyedi, MBChB, PhD, MPH, acting director of the Farncombe Family Health Research Institute and director of the Division of Gastroenterology at McMaster University in Hamilton, Ontario, Canada. Four of the 27 patients with mild to moderate ulcerative colitis who received an FMT enema achieved clinical remission (Mayo score of 2 or less and endoscopic Mayo score of 0), while two of the 26 patients who received a placebo enema achieved clinical remission. More patients experienced improvements than achieved remission, with seven FMT patients and eight placebo patients seeing improvements in their Mayo scores by 30% or more. All patients began the study with Mayo scores of 4 or more and endoscopic Mayo scores of 1 or greater. No significant adverse effects we
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *